Cargando…
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Maintaining the balance between eliciting immune responses against foreign proteins and tolerating self-proteins is crucial for maintenance of homeostasis. The functions of programmed death protein 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1) are to inhibit immune responses so that over...
Autores principales: | Kumar, Sunny, Chatterjee, Mouli, Ghosh, Pratyasha, Ganguly, Kirat K., Basu, Malini, Ghosh, Mrinal K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311058/ https://www.ncbi.nlm.nih.gov/pubmed/37397537 http://dx.doi.org/10.1016/j.gendis.2022.07.024 |
Ejemplares similares
-
COVID-19 and cancer: insights into their association and influence on genetic and epigenetic landscape
por: Ghosh, Mrinal K, et al.
Publicado: (2023) -
Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022) -
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
por: Kumar, Sunny, et al.
Publicado: (2023) -
PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
por: Ghosh, Joydeep, et al.
Publicado: (2021) -
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)